Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD) [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing umeclidinium bromide/vilanterol to fluticasone propionate/salmeterol in COPD over 12 weeks assessing efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Fluticasone propionate/salmeterol (fluticasone propionate/salmeterol)
• umeclidinium bromide/vilanterol

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 3 | Status: COMPLETED | Results posted: 2014-05-29